Seres Therapeutics Provides Corporate Updates and Financial Results

On January 9, 2025, Seres Therapeutics, Inc. (NASDAQ: MCRB) released significant updates regarding its recent achievements and financial standing. The company shared details from its preliminary financial results, new translational biomarker findings from the SER-155 Phase 1b clinical study in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), as well as corporate developments.

The translational biomarker results from the SER-155 Phase 1b study demonstrated a notable decrease in fecal albumin and positive impacts on biomarkers of systemic inflammation and immune homeostasis compared to placebo. These results align with SER-155’s mechanism of action, indicating the potential to reduce bloodstream infections by promoting epithelial barrier integrity.

Moreover, the US Food and Drug Administration (FDA) granted Breakthrough Therapy designation to SER-155 for its efficacy in reducing bloodstream infections in adults undergoing allo-HSCT. The company submitted a Briefing Book supporting its proposed interaction with the FDA for a potential next registrational study of SER-155 and expects feedback in the first quarter of 2025.

Financially, Seres Therapeutics reported approximately $31 million in cash and cash equivalents as of December 31, 2024. With anticipated installment payments totaling around $75 million from Nestlé Health Science and current operational plans, including planned investments for the next SER-155 study, the company expects to fund its operations into the first quarter of 2026.

Seres Therapeutics underlined its commitment to advancing the clinical development of SER-155 and engaging with potential partners to maximize the therapeutic opportunity. The company noted the significance of the new biomarker data in expanding the understanding of SER-155’s potential in preventing infections in vulnerable patient populations beyond allo-HSCT.

The company’s efforts have been met with positive responses from healthcare professionals and payers, acknowledging the unmet need for effective treatments in preventing bloodstream infections in patients undergoing allo-HSCT. This underscores the clinical and commercial value proposition of SER-155.

Seres Therapeutics, a clinical-stage company focusing on innovative live biotherapeutics, continues to make strides in developing treatments that target a range of diseases through its biotherapeutic candidates. The company’s dedication to advancing treatment options for medically vulnerable populations reaffirms its commitment to improving patient outcomes through novel therapeutic interventions.

For more information on Seres Therapeutics and its pipeline programs, interested parties can visit their official website.

Contact:
[email protected]
Carlo Tanzi, Ph.D.
Kendall Investor Relations
[email protected]

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Seres Therapeutics’s 8K filing here.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.